Literature DB >> 21948966

Waves of trouble: MRSA strain dynamics and assessment of the impact of infection control.

David Wyllie1, John Paul, Derrick Crook.   

Abstract

There has been a sustained decline in bloodstream infections due to methicillin-resistant Staphylococcus aureus (MRSA) throughout the UK. The UK MRSA epidemic, which began in the 1990s, has been dominated by two epidemic MRSA (EMRSA) clones {EMRSA-15, of clonal complex (CC) 22 [sequence type (ST) 22], and EMRSA-16, of CC30 (ST36)}. It appears that both these clones followed a wave trajectory (initial expansion, relative stasis, then decline). Three recent studies have shown that ST36 has declined faster than ST22, a change that appears to have begun before the recent intensification of intensive control measures in the UK. The biological basis of infectious disease waves, including those of MRSA, is discussed, as are the implications of such waves for the assessment of the impact of infection control measures.

Entities:  

Mesh:

Year:  2011        PMID: 21948966     DOI: 10.1093/jac/dkr392

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  25 in total

1.  Human Microbiome Inspired Antibiotics with Improved β-Lactam Synergy against MDR Staphylococcus aureus.

Authors:  John Chu; Xavier Vila-Farres; Daigo Inoyama; Ricardo Gallardo-Macias; Mark Jaskowski; Shruthi Satish; Joel S Freundlich; Sean F Brady
Journal:  ACS Infect Dis       Date:  2017-09-11       Impact factor: 5.084

2.  Outbreak Column 12: Nosocomial Staphylococcus aureus outbreaks (part 1).

Authors:  Evonne T Curran
Journal:  J Infect Prev       Date:  2013-11-28

3.  Outbreak Column 13: Nosocomial Staphylococcus aureus outbreaks (part 2 - guidelines).

Authors:  Evonne T Curran
Journal:  J Infect Prev       Date:  2014-02-28

4.  Re-emergence of methicillin susceptibility in a resistant lineage of Staphylococcus aureus.

Authors:  Alice Ledda; James R Price; Kevin Cole; Martin J Llewelyn; Angela M Kearns; Derrick W Crook; John Paul; Xavier Didelot
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.790

5.  Synthesis and antibacterial evaluation of a novel series of synthetic phenylthiazole compounds against methicillin-resistant Staphylococcus aureus (MRSA).

Authors:  Haroon Mohammad; P V Narasimha Reddy; Dennis Monteleone; Abdelrahman S Mayhoub; Mark Cushman; Mohamed N Seleem
Journal:  Eur J Med Chem       Date:  2015-03-07       Impact factor: 6.514

Review 6.  Surveillance of antibiotic resistance.

Authors:  Alan P Johnson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-06-05       Impact factor: 6.237

7.  Staphylococcus aureus bacteremia at 5 US academic medical centers, 2008-2011: significant geographic variation in community-onset infections.

Authors:  Michael Z David; Robert S Daum; Arnold S Bayer; Henry F Chambers; Vance G Fowler; Loren G Miller; Belinda Ostrowsky; Alison Baesa; Susan Boyle-Vavra; Samantha J Eells; Sylvia Garcia-Houchins; Philip Gialanella; Raul Macias-Gil; Thomas H Rude; Felicia Ruffin; Julia J Sieth; Joann Volinski; Brad Spellberg
Journal:  Clin Infect Dis       Date:  2014-05-30       Impact factor: 9.079

Review 8.  Methicillin-Resistant Staphylococcus aureus: Molecular Characterization, Evolution, and Epidemiology.

Authors:  Sahreena Lakhundi; Kunyan Zhang
Journal:  Clin Microbiol Rev       Date:  2018-09-12       Impact factor: 26.132

9.  Microevolutionary events involving narrow host plasmids influences local fixation of vancomycin-resistance in Enterococcus populations.

Authors:  Ana R Freitas; Carla Novais; Ana P Tedim; María Victoria Francia; Fernando Baquero; Luísa Peixe; Teresa M Coque
Journal:  PLoS One       Date:  2013-03-29       Impact factor: 3.240

10.  Genetic structure of community acquired methicillin-resistant Staphylococcus aureus USA300.

Authors:  Ryan Tewhey; Christopher R Cannavino; John A D Leake; Vikas Bansal; Eric J Topol; Ali Torkamani; John S Bradley; Nicholas J Schork
Journal:  BMC Genomics       Date:  2012-09-25       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.